Study of 4-drug treatment for newly diagnosed high-risk mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 80 and can give consent (or your legal representative can).
- Your biopsy confirms mantle cell lymphoma (MCL) and your tumor shows the t(11;14) change and/or cyclin D1/SOX11 pattern.
- You are newly diagnosed and need MCL treatment, with no prior anti-cancer treatment for MCL (except limited prior radiation).
- Your MCL is “high risk,” such as fast-growing tumor, bulky disease, TP53/17p changes, or a high MIPI score, based on lab/pathology results.
- Your blood counts and organ tests are high enough (neutrophils, platelets, hemoglobin, liver and kidney numbers).
- You can swallow oral pills/capsules and agree to birth-control rules if you can get pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) for people with high-risk mantle cell lymphoma. The goal is to see if the combination works better than standard treatments, and it may be an option if your lymphoma has not responded well or has certain aggressive features.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.